Baltimore AI Company Plans New Orleans Pilot for FDA Clearance
1 report, 1 independent
Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A Baltimore-based AI company planned a clinic pilot in New Orleans. This pilot uses AI software to analyze retinal images for signs of eye and neurological diseases. The initiative was intended to provide feedback for the company’s FDA clearance application, which is part of the 2026 BioChallenge competition in New Orleans.
From technical.ly
Why it matters
The BioChallenge competition in New Orleans brings together entrepreneurs, investors, and researchers to advance technologies for conditions like Alzheimer’s disease. Successful clinical pilots and regulatory approvals are key to bringing new diagnostic tools to patients.
From technical.ly
Who's involved
- New OrleansLocation hosting the 2026 BioChallenge and planned clinical pilot.
- BaltimoreLocation of the Baltimore-based AI company.
- FDARegulatory agency reviewing the AI software for market approval.
- Samantha ScottFounder and CEO of the Baltimore-based AI company.
Keep exploring
The entities involved
-
New Orleans
largest city of the state of Louisiana, United States
-
Baltimore
city in Maryland, United States
- FDA
Related events
- FDA approval enables commercial availability for a product associated with Indianapolis.
- Fate Therapeutics, based in San Diego, is seeking support for an accelerated regulatory pathway from the FDA.
- FDA approval expands patient access to therapies for ACCORD.
- FDA announced regulatory clearance in Salt Lake City on September 25, 2026.